Summary
- Current Price
- As of today, EXEL price is $72.97, up +0.30% in the most recent trading session on
- Current Price All-Time High
- EXEL price is currently -0.64% below its historical high of $73.52 set on
- Market Cap
- EXEL current market cap is $18B, up +64.51% over the past 365 days
- PE Ratio
- EXEL current PE ratio is 21.84
- Revenue
- EXEL current annual revenue is $2.32B, up +6.98% year-over-year
- Next Earnings
- The next earnings release for EXEL is on
Profile
| Metric | Value |
|---|---|
| Full Name | Exelixis, Inc. |
| Ticker | NASDAQ: EXEL |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | exelixis.com |
| Employees | 1,147 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $72.97 | |
| Price, 1D Change | +0.30% | |
| Market Cap | $18B | |
| - | ||
| PE Ratio | 21.84 | |
| Beta | 0.53 | |
| Revenue | $2.32B | |
| Revenue, 1Y Change | +6.98% | |
| EPS | $2.78 | |
| EPS, 1Y Change | +57.73% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | EXL1V | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $2.78 | |
| EPS Estimate | $3.75 | |
| EPS Est. Change | +34.89% | |
| Revenue | $2.32B | |
| Revenue Estimate | $2.55B | |
| Revenue Est. Change | +10.12% | |
| Current Price | $72.97 | |
| Price Target | $59.00 | - |
| Price Tgt. Change | -19.14% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.94 | $1.76 | -9.43% | |
| $2.96 | $2.78 | -6.32% | |
| $3.75 | N/A | +34.89% | |
| $4.29 | N/A | +54.36% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.16B | $2.17B | +0.21% | |
| $2.32B | $2.32B | -0.09% | |
| $2.55B | N/A | +10.12% | |
| $2.90B | N/A | +25.15% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +80.75% | |
| Price, 3Y | +247.48% | |
| Market Cap, 1Y | +64.51% | |
| Market Cap, 3Y | +172.66% | |
| Revenue, 1Y | +6.98% | |
| Revenue, 3Y | +44.01% | |
| EPS, 1Y | +57.73% | |
| EPS, 3Y | +394.37% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $72.97 | |
| SMA 200 | $51.32 | |
| SMA 50 | $60.38 | |
| EMA 200 | $53.10 | |
| EMA 50 | $61.46 | |
| MACD | $3.23 | |
| Beta | 0.53 | |
| ATR | $2.06 | |
| 14-Day RSI | 86.16 | |
| 10-Day Volatility | 26.67% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $2.32B | |
| EPS | $2.78 | |
| Gross Profit | $2.24B | |
| Gross Margin | 96.39% | |
| Operating Income | $892.70M | |
| Operating Margin | 38.48% | |
| Net Income | $782.57M | |
| Net Margin | 33.73% | |
| EBITDA | $921.76M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.09 | |
| 3.56 | ||
| 3.50 | ||
| - | ||
| 7 | ||
| 17.05 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 21.84 | |
| 7.13 | ||
| 9.71 | ||
| 16.55 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $2.16B | |
| $1.06B | ||
| $2.88B | ||
| $1.44B | ||
| $720.71M | ||
| $405.64M | ||
| Total Debt | $200.92M | |
| $27.88M | ||
| $29.62M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $1.54B | ||
| $1.34B | ||
| $83.70M | ||
| $0.00 | ||
| $29.06M | ||
| $0.00 | ||
| $158.64M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $884.27M | ||
| $350.44M | ||
| -$969.59M | ||
| Capex | $8.43M | |
| $875.84M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Truist Securities | → | |
| TD Cowen | → | |
| RBC Capital | → | |
| Morgan Stanley | → | |
| Barclays | → | |
| Citizens | → | |
| RBC Capital | → | |
| RBC Capital | → | |
| Truist Securities | → | |
| BMO Capital | → |
Analyst sentiment
Institutional ownership
No data
Screeners with EXEL
FAQ
- What is the ticker symbol for Exelixis, Inc.?
- The ticker symbol for Exelixis, Inc. is NASDAQ:EXEL
- Does Exelixis, Inc. pay dividends?
- No, Exelixis, Inc. does not pay dividends
- What sector is Exelixis, Inc. in?
- Exelixis, Inc. is in the Healthcare sector
- What industry is Exelixis, Inc. in?
- Exelixis, Inc. is in the Biotechnology industry
- What country is Exelixis, Inc. based in?
- Exelixis, Inc. is headquartered in United States
- When did Exelixis, Inc. go public?
- Exelixis, Inc. initial public offering (IPO) was on April 17, 2000
- Is Exelixis, Inc. in the S&P 500?
- No, Exelixis, Inc. is not included in the S&P 500 index
- Is Exelixis, Inc. in the NASDAQ 100?
- No, Exelixis, Inc. is not included in the NASDAQ 100 index
- Is Exelixis, Inc. in the Dow Jones?
- No, Exelixis, Inc. is not included in the Dow Jones index
- When was Exelixis, Inc. last earnings report?
- Exelixis, Inc.'s most recent earnings report was on October 29, 2026
- When does Exelixis, Inc. report earnings?
- The next expected earnings date for Exelixis, Inc. is February 9, 2027
Data Sources & References
- EXEL Official Website www.exelixis.com
- EXEL Profile on Yahoo Finance finance.yahoo.com/quote/EXEL
- EXEL Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/exel
